Zhongzhi Pharmaceutical Holdings (HKSE:03737) Debt-to-Equity : 0.22 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Zhongzhi Pharmaceutical Holdings Debt-to-Equity?

Zhongzhi Pharmaceutical Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$138 Mil. Zhongzhi Pharmaceutical Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$109 Mil. Zhongzhi Pharmaceutical Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,147 Mil. Zhongzhi Pharmaceutical Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zhongzhi Pharmaceutical Holdings's Debt-to-Equity or its related term are showing as below:

HKSE:03737' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.2 Max: 0.23
Current: 0.22

During the past 10 years, the highest Debt-to-Equity Ratio of Zhongzhi Pharmaceutical Holdings was 0.23. The lowest was 0.12. And the median was 0.20.

HKSE:03737's Debt-to-Equity is ranked better than
57.55% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:03737: 0.22

Zhongzhi Pharmaceutical Holdings Debt-to-Equity Historical Data

The historical data trend for Zhongzhi Pharmaceutical Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongzhi Pharmaceutical Holdings Debt-to-Equity Chart

Zhongzhi Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.17

0.23

0.20

0.21

0.22

Zhongzhi Pharmaceutical Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.20	0.17	0.21	0.19	0.22

Competitive Comparison of Zhongzhi Pharmaceutical Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Zhongzhi Pharmaceutical Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhongzhi Pharmaceutical Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhongzhi Pharmaceutical Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zhongzhi Pharmaceutical Holdings's Debt-to-Equity falls into.

Zhongzhi Pharmaceutical Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zhongzhi Pharmaceutical Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(137.582	+	108.585)	/	1146.845
	=	0.21

Zhongzhi Pharmaceutical Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(137.582	+	108.585)	/	1146.845
	=	0.21

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zhongzhi Pharmaceutical Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zhongzhi Pharmaceutical Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhongzhi Pharmaceutical Holdings Ltd (HKSE:03737) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN

Website

https://www.zeus.cn

Zhongzhi Pharmaceutical Holdings Ltd is engaged in the business of manufacturing and selling pharmaceutical products. The group's operations can be divided into three segments, namely Pharmaceutical manufacturing, Operation of chain pharmacies, and Operation of online pharmacies in Zhongshan in the Guangdong province, the PRC. In the Pharmaceutical manufacturing segment, the company is engaged in the research and development, manufacturing and sale of Chinese patent medicines. In the Operation of chain pharmacies segment, the firm operates chain pharmacies in Zhongshan under the brand Zeus for the sale of pharmaceutical products. The Operation of online pharmacies segment sells medicines online. It derives a majority of its revenue from the PRC.

Executives

Jiang Li Xia	2202 Interest of your spouse
Lai Zhi Tian	2201 Interest of corporation controlled by you
Crystal Talent Investment Group Limited	2101 Beneficial owner
Cheng Jin Le	2201 Interest of corporation controlled by you
Advance Keypath Global Investment Limited	2101 Beneficial owner
Novich Positioning Investment (cayman) Limited	2201 Interest of corporation controlled by you
Novich Positioning Investment Limited Partnership	2101 Beneficial owner

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Headlines

No Headlines